ADCs headline first-in-human development at ASCO 

It was another year of translational antibody-drug conjugate innovation at ASCO, where a diversity of payloads, designs, and targets featured as one of the year’s big trends in first-in-human research. The modality was the focus of 20% of the conference’s first-in-human trials, quieting any doubts that ADC interest has peaked. 

Consistent with trends across the industry, China featured prominently as both a source of translational programs and a site for early-stage clinical research, though U.S. biopharmas retained an edge in first-in-class clinical research...